Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 6/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 6/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 5/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27128981 | 1.00 | RXRA (0.43) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL29926019 | 0.86 | RXRA (0.52) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL27130754 | 0.86 | RXRA (0.52) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL27032492 | 0.86 | RXRA (0.52) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL27032495 | 0.84 | RXRA (0.43) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL27131515 | 0.83 | RXRA (0.46) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL27032545 | 0.83 | RXRA (0.46) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL29926005 | 0.83 | RXRA (0.46) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL29925848 | 0.81 | BRD4 (0.31) | BRD4HRH3MEN1KMT2A | |
| SCHEMBL27031963 | 0.81 | BRD4 (0.31) | BRD4HRH3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | SERVIER LAB (FR) | 2024-07-25 | — | — | US | disclosed |
| EP-4308570-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | Les Laboratoires Servier (FR) | 2024-01-24 | — | — | EP | disclosed |
| CN-117425661-A | Macrocyclic LRRK2 kinase inhibitors | 法国施维雅药厂 | 2024-01-19 | — | — | CN | disclosed |
| WO-2022194976-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246992-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, PARK7, PINK1 | RXRA 4834/4885RXRB 4763/4885RXRG 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.